[Paraneoplastic opsoclonus-myoclonus syndrome--a review]

Hideyuki Matsumoto1, Yoshikazu Ugawa

  • 1Department of Neurology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

Insights

Paraneoplastic opsoclonus-myoclonus syndrome (POMS) involves chaotic eye movements and myoclonus, often linked to cancers. Research is needed for better POMS treatments, especially given its neurological sequelae.

Area of Science:

  • Neurology
  • Immunology
  • Oncology

Context:

  • Paraneoplastic opsoclonus-myoclonus syndrome (POMS) presents with opsoclonus, ataxia, and myoclonus.
  • POMS is associated with specific cancers (lung, breast, ovarian in adults; neuroblastoma in children).
  • Differential diagnoses include parainfectious encephalitis and toxic-metabolic conditions.

Purpose:

  • To review the clinical features, potential causes, and immunopathogenesis of POMS.
  • To discuss current therapeutic strategies and their limitations in POMS management.
  • To highlight the need for further research into POMS pathophysiology and novel treatments.

Summary:

  • POMS is characterized by involuntary saccadic eye movements and myoclonus, frequently linked to underlying malignancies.
  • Autoantibodies suggest humoral immunity, but seronegativity implies a role for cell-mediated immunity in POMS pathogenesis.
  • Cerebellar fastigial nucleus disinhibition is a proposed mechanism, though POMS pathophysiology requires further elucidation.

Impact:

  • Understanding POMS immunopathogenesis is crucial for developing targeted therapies.
  • Effective POMS treatment, especially in children, requires addressing neurological sequelae.
  • Improved therapeutic strategies are needed for POMS, particularly in adults where tumor resection is key.

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...